S'abonner

Acinetobacter species in the skin microbiota protect against allergic sensitization and inflammation - 05/12/14

Doi : 10.1016/j.jaci.2014.07.059 
Nanna Fyhrquist, PhD a, Lasse Ruokolainen, PhD b, Alina Suomalainen, BSc a, Sari Lehtimäki, PhD c, Ville Veckman, PhD a, Johanna Vendelin, PhD a, Piia Karisola, PhD a, Maili Lehto, PhD a, Terhi Savinko, PhD d, Hanna Jarva, MD e, Timo U. Kosunen, MD e, Jukka Corander, PhD f, Petri Auvinen, PhD d, Lars Paulin, PhD d, Leena von Hertzen, PhD g, Tiina Laatikainen, PhD h, i, Mika Mäkelä, MD g, Tari Haahtela, MD g, Dario Greco, PhD a, Ilkka Hanski, PhD b, Harri Alenius, PhD a,
a Unit of Systems Toxicology, Finnish Institute of Occupational Health, Helsinki, Finland 
b Department of Biosciences, University of Helsinki, Helsinki, Finland 
d Institute of Biotechnology, University of Helsinki, Helsinki, Finland 
c Molecular Immunology Group, Turku Centre for Biotechnology, Turku, Finland 
e Haartman Institute, Department of Bacteriology and Immunology and Research Programs Unit, Immunobiology, University of Helsinki, and Helsinki University Central Hospital Laboratory (HUSLAB), Helsinki, Finland 
f Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland 
g Allergy Department, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland 
h Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland 
i Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland 

Corresponding author: Harri Alenius, PhD, Unit of Systems Toxicology, Finnish Institute of Occupational Health, Topeliuksenkatu 41 b, Helsinki-FIN 00250, Finland.

Abstract

Background

The human commensal microbiota interacts in a complex manner with the immune system, and the outcome of these interactions might depend on the immune status of the subject.

Objective

Previous studies have suggested a strong allergy-protective effect for Gammaproteobacteria. Here we analyze the skin microbiota, allergic sensitization (atopy), and immune function in a cohort of adolescents, as well as the influence of Acinetobacter species on immune responses in vitro and in vivo.

Methods

The skin microbiota of the study subjects was identified by using 16S rRNA sequencing. PBMCs were analyzed for baseline and allergen-stimulated mRNA expression. In in vitro assays human monocyte-derived dendritic cells and primary keratinocytes were incubated with Acinetobacter lwoffii. Finally, in in vivo experiments mice were injected intradermally with A lwoffii during the sensitization phase of the asthma protocol, followed by readout of inflammatory parameters.

Results

In healthy subjects, but not in atopic ones, the relative abundance of Acinetobacter species was associated with the expression of anti-inflammatory molecules by PBMCs. Moreover, healthy subjects exhibited a robust balance between anti-inflammatory and TH1/TH2 gene expression, which was related to the composition of the skin microbiota. In cell assays and in a mouse model, Acinetobacter species induced strong TH1 and anti-inflammatory responses by immune cells and skin cells and protected against allergic sensitization and lung inflammation through the skin.

Conclusion

These results support the hypothesis that skin commensals play an important role in tuning the balance of TH1, TH2, and anti-inflammatory responses to environmental allergens.

Le texte complet de cet article est disponible en PDF.

Key words : Atopy, Gammaproteobacteria, Acinetobacter species, PBMC, anti-inflammatory gene expression, dendritic cells, keratinocytes, mouse asthma model

Abbreviations used : ACTB, AHR, DC, FOXP3, GAPDH, moDC, OVA, PE, qPCR, TLR2, Treg


Plan


 The research leading to these results has received funding from the Academy of Finland (grants nos. 138695, 255350, 121025, and 251170), the European Research Council (grant no. 239784), the Jane and Aatos Erkko Foundation, Helsinki University Hospital (HUS) (grant no. 8361), and by the European Union's Seventh Framework Programme FP7/2007-2013 under grant agreements 261366 (MAARS) and 261357 (MeDALL).
 Disclosure of potential conflict of interest: This study was funded by the Academy of Finland (grants nos. 138695, 255350, 121025, and 251170), the European Research Council (grant no. 239784), the Jane and Aatos Erkko Foundation, the European Union's Seventh Framework Programme (grant agreements 261366 and 261357), and the Helsinki University Hospital (grant no. 8361). T. Haahtela is on the board of the Global Initiative for Asthma, and has received payment for delivering lectures from OrionPharma and Merck. The rest of the authors declare that they have no relevant conflicts of interest.


© 2014  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 134 - N° 6

P. 1301 - décembre 2014 Retour au numéro
Article précédent Article précédent
  • Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
  • Jennifer D. Hamilton, Mayte Suárez-Fariñas, Nikhil Dhingra, Irma Cardinale, Xuan Li, Ana Kostic, Jeffrey E. Ming, Allen R. Radin, James G. Krueger, Neil Graham, George D. Yancopoulos, Gianluca Pirozzi, Emma Guttman-Yassky
| Article suivant Article suivant
  • Oral immunotherapy induces IgG antibodies that act through Fc?RIIb to suppress IgE-mediated hypersensitivity
  • Oliver T. Burton, Stephanie L. Logsdon, Joseph S. Zhou, Jaciel Medina-Tamayo, Azza Abdel-Gadir, Magali Noval Rivas, Kyle J. Koleoglou, Talal A. Chatila, Lynda C. Schneider, Rima Rachid, Dale T. Umetsu, Hans C. Oettgen

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.